David Hanley

Dr. Hanley joined Nuvation Bio in 2021, bringing 20 years of pharmaceutical industry experience driving strategy for technical operations and chemistry manufacturing and controls (CMC), including virtual networks, for drug development, manufacturing and distribution in the U.S. and worldwide. He holds diverse disease expertise, including oncology, central nervous system (CNS) and autoimmune, and product types, including biologics, small molecule therapies, cell therapies and synthetic peptide products.

Dr. Hanley most recently served as Senior Vice President and Head of Global Pharmaceutical Development and Operations at BioXcel Therapeutics, where he led strategy and execution for CMC development, end-to-end supply chain and external supply manufacturing. Prior, Dr. Hanley held positions at Radius Health, Inc., including Vice President of Pharmaceutical Sciences and Technical Operations. There, he led the end-to-end supply chain, including for CMC development, a U.S. Food and Drug Administration (FDA) New Drug Application (NDA) and FDA-approved product launch. Dr. Hanley also held leadership positions at The Medicines Company, including Senior Director of Global Pharmaceutical Development, and project management and scientific positions at Medarex and Berlex, a subsidiary of Schering AG, at the start of his career.

Dr. Hanley earned his Ph.D. in Physical and Analytical Chemistry from the University of Utah and his B.S. in Chemistry from Virginia Commonwealth University.